Blood donation centers do test for several sexually transmitted infections, but they do not screen for every STD. In most countries, every donated unit is tested for HIV, hepatitis B, hepatitis C, and syphilis at a minimum. Some centers also screen for additional viruses depending on geography and local risk. The testing is thorough for what it covers, but it is designed to protect the blood supply, not to serve as a personal health check. That distinction matters more than most donors realize.
What Infections Are Tested For
The standard panel of tests performed on donated blood targets a core group of infections that can survive in stored blood products and infect a transfusion recipient. In the United States, the American Red Cross and other collection agencies test every unit for HIV-1 and HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis (caused by the bacterium Treponema pallidum), West Nile virus, and human T-lymphotropic virus (HTLV-I and HTLV-II). Trypanosoma cruzi, the parasite that causes Chagas disease, is also screened for, and in some cases Zika virus testing is performed depending on the epidemiological situation. Babesia, a tick-borne parasite, has more recently been added to the testing panel in certain parts of the United States.
Other countries test for a similar but not identical set of infections. The universal four across virtually all blood services worldwide are HIV, HBV, HCV, and syphilis. A study spanning eleven years at a Nigerian tertiary hospital found that roughly 15% of prospective donors were infected with at least one of these four agents, with individual prevalences ranging from about 3% to 4% each for HBV, HCV, syphilis, and HIV.1BMC Public Health. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation Those numbers are far higher than what you would see in countries with established voluntary donor systems, but they illustrate why universal testing is non-negotiable.
How the Tests Work
Blood banks rely on two complementary testing strategies. The first is serology, which looks for antibodies or antigens your immune system produces in response to an infection. The second is nucleic acid testing, commonly called NAT, which hunts for the actual genetic material of a virus in the blood. Using both methods together catches more infections than either method alone.
Serology has been the backbone of blood screening for decades. It is good at detecting infections once the immune system has mounted a response. NAT, on the other hand, can detect a virus’s genetic material before the body has made antibodies, which closes part of the dangerous gap between when someone gets infected and when traditional tests can pick it up. A large international review found that NAT adoption has grown substantially over the past decade, and in 2019 alone, NAT-positive donations were identified for HIV, HCV, HBV, hepatitis E virus, West Nile virus, and Zika virus across surveyed countries. Globally, over 3,100 donations were flagged solely by NAT in that year, and more than 22,000 had been caught by NAT since the technology was introduced, with HBV accounting for over half.2PubMed. International review of blood donation nucleic acid amplification testing That means thousands of infected units would have entered the blood supply if the older testing methods were the only line of defense.
A comparative study from Saudi Arabia confirmed the practical value of running both screening methods, concluding that NAT and serology provide complementary information and that combined strategies are the way forward for transfusion safety.3PubMed Central. Prevalence of Transfusion-Transmitted Viral Infections Among Blood Donors in Riyadh, Saudi Arabia: A Comparative Analysis of Nucleic Acid Testing and Serological Screening
The Window Period Problem
No test can detect an infection the moment it enters your body. After exposure to a virus like HIV or hepatitis C, there is a stretch of days or weeks when the virus is multiplying but has not yet reached levels detectable by even the most sensitive tests. This is called the window period, and it is the single biggest vulnerability in the blood screening system.
NAT has shortened this window considerably compared to older antibody-only tests, but it has not eliminated it entirely. A U.S. monitoring study covering 2017 to 2023 estimated the residual risk of an infected donation slipping through all screening. For HIV, the risk worked out to roughly 0.23 per million donations; for HBV, about 0.43 per million; and for HCV, about 0.16 per million when measured over a recent three-month period.4PubMed Central. Incidence and window period residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2017 to 2023 Those are extraordinarily low numbers, but they are not zero. The window period is the reason blood banks layer additional safeguards on top of laboratory testing.
The Pre-Donation Questionnaire
Before your blood ever reaches a test tube, you go through a detailed screening questionnaire designed to flag behaviors and exposures that raise the risk of carrying an infection. This questionnaire, known formally as the Donor Health Questionnaire, asks about recent travel, tattoos, piercings, sexual history, intravenous drug use, history of jaundice, and other potential risk factors. It serves as a first filter, catching some high-risk donors before they donate rather than relying solely on the lab to catch infected blood afterward.
The questionnaire is not perfect. Research has consistently shown that donors sometimes do not fully disclose risk behaviors. A review of the questionnaire’s effectiveness noted that it has relatively high rates of non-compliance, and that donors tend to do their own risk assessment when filling it out, sometimes deciding that a particular question does not apply to them even when it does.5ISBT Science Series. Effectiveness of predonation health and travel screening in reducing the risk of transfusion‐transmitted infections A German study estimated that fully capturing heterosexual risk contacts through the questionnaire could prevent acceptance of about half of HIV-infected donors, and that better recording of piercing and tattoo history could catch an additional fraction of HCV-infected donors.6PubMed Central. Which Infectious Blood Donors Could Be Identified by the Donor History Questionnaire?
Policies around the questionnaire have evolved significantly. The most visible change in recent years involves donors who are men who have sex with men. In 2023, the FDA moved away from blanket deferrals based on sexual orientation, shifting instead to an individualized risk assessment. Under the updated guidance, all prospective donors, regardless of sex or gender identity, are asked about new or multiple sexual partners within the past three months, followed by a question about anal sex in the same time frame.7JAMA Health Forum. FDA’s 2023 Policy Update—Promoting Safety and Inclusivity in Blood Donation This replaced the earlier approach used in many countries, where men who had sex with men were deferred based on a period of abstinence, often twelve months.8PubMed. Donor deferral policies for men who have sex with men: past, present and future
What Happens If You Test Positive
If your donated blood tests positive on any screening marker, the blood is discarded and you will be contacted. How notification works varies by organization and by country, but the general pattern is consistent: you are told about the result and referred for confirmatory testing and medical follow-up.
At Canadian Blood Services, donors with confirmed positive results for any infectious marker are notified by registered letter. Those who test positive for HIV or West Nile virus are also contacted by phone. The notification explains that the donor is “very likely” infected with the specific agent, and if the donor has given blood before, previous donations will be investigated to see whether a recipient may have been infected.9PubMed Central. Notification of blood donors who test positive for transfusion-transmissible infections Similar processes operate in other countries. In one Indian blood bank system, a counselor contacts the donor by phone about the abnormal result and advises them to come in for one-on-one counseling, repeat sampling, and referral for further medical care.10Global Journal of Transfusion Medicine. Blood Donor Notification and Counseling of Reactive Test Result in Blood Bank of South Gujarat
In most systems, a positive screening result also means you are deferred from donating in the future, sometimes temporarily and sometimes permanently depending on the infection and the confirmatory test results. Your name typically enters a donor deferral registry.
False Positives and What They Mean for Donors
Blood screening tests are set to be extremely sensitive, which means they are tuned to catch every possible true positive. The trade-off is that they occasionally flag donors who are not actually infected. A false positive result on a blood donation test can be a genuinely distressing experience, particularly when the notification letter tells you that you are “very likely” infected with something like HIV or hepatitis.
The problem is not trivial. Interpreting borderline results can be complicated, especially when a serological confirmatory test comes back indeterminate but no viral genetic material is found, or when certain antibody patterns could represent either a past cleared infection or a testing artifact.11PubMed. False positive viral marker results in blood donors and their unintended consequences Some donors who receive false positive notifications report lasting psychological effects, including anxiety and relationship strain, even after follow-up testing confirms they are not infected. Blood services have developed strategies to minimize these situations, including refining confirmatory testing algorithms and improving how notification letters are worded, but it remains an unavoidable consequence of running screening tests that prioritize sensitivity above all else.
What Blood Banks Do Not Test For
This is where the answer to the title question gets important for anyone thinking of using blood donation as a proxy for STD screening. Blood banks do not test for many common sexually transmitted infections. Herpes simplex virus (HSV-1 and HSV-2), human papillomavirus (HPV), chlamydia, and gonorrhea are not part of standard blood donation testing anywhere in the world. These infections either do not survive well in stored blood, are not efficiently transmitted through transfusion, or both.
Syphilis offers an interesting case study in the relationship between transfusion risk and testing practice. Transfusion-transmitted syphilis is extremely rare in modern practice because the bacterium Treponema pallidum does not survive more than about 72 hours when blood is stored at refrigerator temperatures. Combined with the donor questionnaire and routine serological screening, this makes transfusion-transmitted syphilis essentially a historical concern rather than a current one.12Europe PMC. Syphilis testing in blood donors: an update Yet syphilis testing remains universal on donated blood. The rationale is partly that a syphilis-positive result is a useful marker for other high-risk exposures, and partly that it is inexpensive enough to keep running.
The key takeaway: if you want to know your STD status, go to a sexual health clinic or ask your doctor for a full panel. A blood donation will tell you about HIV, hepatitis B, hepatitis C, and syphilis if you happen to test positive, but it will miss the most common STDs entirely and is not designed to give you a personal health report.
Why You Should Not Donate Blood to Get Tested
Some people do donate blood primarily to find out whether they have HIV or another infection. A study from Scandinavia found that about 2.8% of surveyed donors reported giving blood in order to be HIV tested. The reassuring finding was that 87% of that group did not have any identified risk behavior. Still, the remaining fraction did, and those donors represent a real problem for blood safety.13PubMed. Risk behaviour among blood donors who give blood in order to be tested for the human immunodeficiency virus
The concern is straightforward. If someone donates during the window period of a new infection, the lab tests may not catch it, and the blood could reach a patient. Free and confidential STD testing is widely available through public health clinics, community health centers, and many pharmacies. These services are specifically designed to give you personal results, with counseling and referral to treatment. Blood donation testing is designed to protect the recipient of the transfusion, and the notification process, while it does exist, is slower and less comprehensive than what you would get at a clinic.
To address this concern, many blood services have historically used a tool called confidential unit exclusion, or CUE. After the donation, the donor is privately asked to indicate whether their blood should actually be used for transfusion. The idea is that someone who felt pressured into donating at a workplace drive, or who was too embarrassed to disclose a risk factor in front of others, could quietly flag their own blood for discard. A Brazilian study found that CUE was effective and inexpensive but had low diagnostic power for detecting actual infections, resulting in the discard of many safe units.14PubMed Central. Effectiveness of confidential unit exclusion in screening blood donors of the regional blood bank in Londrina, Paraná State An Iranian study found that first-time donors were more likely to use CUE, suggesting that high-risk individuals sometimes do use donation as a way to find out whether they are infected.15PubMed Central. Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population Many blood services have since moved away from CUE, relying instead on improved NAT screening and better questionnaire design.
Pathogen Reduction Technologies
Testing is not the only defense against contaminated blood. After collection, some blood products undergo pathogen reduction, a treatment that actively inactivates viruses, bacteria, and parasites in the product. For plasma derivatives, these methods have been spectacularly successful: no transmission of HIV, hepatitis C, or hepatitis B has occurred through U.S.-licensed plasma derivatives since 1987.16PubMed Central. Pathogen-reduction methods: advantages and limits
Several platforms are now in use or advanced development for treating platelets and plasma, including systems that use ultraviolet light combined with chemical agents like amotosalen or riboflavin to damage pathogen DNA so it cannot replicate.17Journal of Umm Al-Qura University for Medical Science. Advances in pathogen reduction technologies: enhancing safety and functionality of blood products These technologies work against a broad spectrum of threats, including ones that current tests do not screen for. Red blood cells are harder to treat this way without damaging the cells themselves, so pathogen reduction for red cell products is still catching up. The European Centre for Disease Prevention and Control has highlighted pathogen reduction as a particularly valuable tool during outbreaks of emerging infections for which no routine laboratory screening yet exists.18PubMed Central. Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union
Emerging Threats and Blood Supply Surveillance
The list of infections that blood services screen for is not fixed. It shifts as new threats appear. West Nile virus was not a concern for U.S. blood banks until the early 2000s. Zika virus entered the screening conversation only after 2015. The challenge is that new pathogens can circulate silently in a population for some time before anyone realizes they pose a transfusion risk. Blood services use a combination of geographic deferrals (blocking donations from travelers to affected regions), rapid deployment of new tests, and the pathogen reduction technologies described above to manage emerging threats.19PubMed Central. Emerging infectious diseases that threaten the blood supply
There is growing interest in flipping the script and using the blood supply itself as a surveillance tool. Because blood donors represent a broad cross-section of the population and are tested regularly, the blood supply offers an unusual window into what infections are circulating in a community. A recent preprint described how arboviruses like dengue, Zika, and West Nile are promising candidates for this kind of surveillance because they often cause asymptomatic infections where viral genetic material can persist in whole blood for weeks, making detection feasible even when the person never felt sick.20medRxiv. Leveraging the U.S. blood supply to detect emerging viral threats
A related and growing concern involves donors who are taking antiretroviral drugs, either as HIV treatment or as pre-exposure prophylaxis (PrEP), without disclosing it. These drugs can suppress HIV to levels that current tests cannot detect, meaning a donor could be HIV-positive, pass all screening tests, and have their blood enter the supply. Brazilian researchers have flagged this as one of the key challenges facing blood safety going forward.21PubMed Central. Transfusion-Acquired HIV: History, Evolution of Screening Tests, and Current Challenges of Unreported Antiretroviral Drug Use in Brazil
How Blood Screening Differs Around the World
If you donate blood in the United States, Canada, Western Europe, Australia, or Japan, you can expect a rigorous multi-layered testing process. That is not the case everywhere. As of the mid-2000s, it was estimated that only about 80% of blood in Africa was being screened for transfusion-transmitted infections at all, and of the countries that reported 100% screening to the World Health Organization, only 71 were performing those tests in a quality-assured manner.22ISBT Science Series. Current screening strategies for blood donor screening in developing countries
The barriers are practical. Resource-limited settings often face inconsistent supplies of testing kits, a shortage of voluntary unpaid donors, and infrastructure challenges that make maintaining cold chains and laboratory equipment difficult.23PubMed Central. Barriers to Effective Transfusion Practices in Limited-Resource Settings: From Infrastructure to Cultural Beliefs Some African countries have moved to NAT screening, including South Africa, Namibia, Egypt, and Ghana, but the cost-effectiveness of doing so in a low-resource setting needs careful evaluation before widespread adoption. Creative approaches have been developed, such as serial testing algorithms that screen for the most prevalent infection first and cascade seronegative samples through subsequent tests, which can substantially cut costs.22ISBT Science Series. Current screening strategies for blood donor screening in developing countries
The Cost of Making Blood Safe
All of this testing costs money, and not every test delivers the same bang for the buck. One U.S. modeling study estimated that adding minipool NAT for HBV, HCV, and HIV to standard serology would prevent roughly 173 additional infections per year and save about 53 life-years, at a net cost of around $154 million, which worked out to about $1.5 million per quality-adjusted life year gained.24PubMed. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States By conventional cost-effectiveness thresholds used in healthcare, that is an extremely high price tag. A multi-country analysis across eight Western nations found that serology screening alone is relatively cost-effective, but the incremental cost of adding NAT on top of serology ranges from about $2.2 million to nearly $16 million per quality-adjusted life year.25PubMed. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries
The numbers get even more dramatic for rarer infections. A South African analysis of universal screening for HTLV-1 and HTLV-2 found that it would cost about $1.6 million per year and prevent fewer than four symptomatic cases, putting the cost per case prevented at roughly $450,000 in the first year and climbing steeply after that.26PubMed Central. Health economic implications of testing blood donors in South Africa for HTLV 1 & 2 infection Countries make different decisions about where to draw the line, and those decisions reflect local prevalence, healthcare budgets, and how much risk a society is willing to accept in its blood supply. The result is that the exact panel of infections tested for when you donate blood depends on where you are in the world, driven as much by economics and epidemiology as by pure science.